Floatz logo

Tas-102

Duct Cell Adenocarcinoma of the Pancreas

Taiho Pharmaceutical Co., Ltd.unclassifiedPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Duct Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Irinotecan
NRG Oncology
Phase 3BB
Inno-206
University Health Network, Toronto
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
PREDNISONE TABLETS
Edward Kim
Phase 2BB
Metformin
British Columbia Cancer Agency
Phase 2BB

View all 23 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →